South Africans’ chances against the imminent third wave of Covid-19 infections may be worse off because of the halting of the Johnson & Johnson vaccine Janssen, says one of the doctors involved in trialling the drug. Dr Hugo Tempelman, CEO of the Ndlovu Care Group which conducted trials for the vaccine last year, says though it’s understandable why first world countries can afford to halt the rollout of the vaccine, the same couldn’t be said about South Africa and other developing nations. Weighing the risks of adverse effects from the vaccine against those faced by South Africa, should it…

first appear on citizen

Leave a Reply

Your email address will not be published. Required fields are marked *